AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

1,457 drug developers and their pipelines

Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.

Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.

← browse by therapeutic area

Views

1457 of 1457 companies

CompanyPipelineMost advancedNext readoutMarket capCash & inv.RunwayR&D / yr
Padagis logo
PadagisPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Palobiofarma SL logo
Palobiofarma SLPrivate
3 assets: 1 Ph 2, 2 Ph 1PBF-680Phase 2 · Chronic Obstructive Pulmonary DiseasePartial signalNone on record————
PAQ Therapeutics, Inc. logo
PAQ Therapeutics, Inc.Private
1 asset: 1 Ph 1PT0511Phase 1 · Non-Small Cell Lung Cancer18 Oct 2028PT0511 · Phase 1————
P
Paragon TherapeuticsPrivate
1 asset: 1 Ph 1APG808Phase 1 · Chronic Obstructive Pulmonary DiseaseNone on record————
Partner Therapeutics, Inc. logo
Partner Therapeutics, Inc.Private
2 assets: 2 approvedApproved assets only31 Dec 2026Zenocutuzumab · Phase 2————
Pathalys Pharma logo
Pathalys PharmaPrivate
1 asset: 1 Ph 3UpacicalcetPhase 3 · Chronic Kidney DiseasePartial signal22 Feb 2032Upacicalcet · Phase 3————
PDC*line Pharma SAS logo
PDC*line Pharma SASPrivate
1 asset: 1 Ph 2PDC*lung01Phase 1/2 · Non-Small Cell Lung CancerWeak signalNone on record————
P
Pediatrix TherapeuticsPrivate
2 assets: 1 approved, 1 Ph 2LepzacitinibPhase 2 · Atopic DermatitisApr 2027Epinephrine · Approved————
P
PendopharmPrivate
1 asset: 1 approvedApproved assets onlyAug 2027palopegteriparatide · Phase 3————
Perha Pharmaceuticals (Fondation Jerome Lejeune spin-off) logo
Perha Pharmaceuticals (Fondation Jerome Lejeune spin-off)Private
1 asset: 1 Ph 1Leucettinib-21Phase 1 · Alzheimer's DiseaseWeak signalNone on record————
PersonGen BioTherapeutics (Suzhou) Co., Ltd. logo
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Private
3 assets: 2 Ph 1, 1 otherUTAA09Phase 1 · Systemic Lupus ErythematosusWeak signal1 Apr 2027UTAA17 · Phase na————
Phanes Therapeutics logo
Phanes TherapeuticsPrivate
1 asset: 1 Ph 2MavrostobartPhase 1/2 · Non-Small Cell Lung CancerDec 2027Mavrostobart · Phase 1/2————
Pharma Two B Ltd. logo
Pharma Two B Ltd.Private
1 asset: 1 Ph 3Pramipexole/rasagiline (P2B001)Phase 3 · Parkinson's DiseaseReliable signalNone on record————
pharmaand logo
pharmaandPrivate
3 assets: 2 approved, 1 otherPanobinostatUS approval withdrawn · Multiple MyelomaPartial signalNone on record————
P
PharmacobioPrivate
1 asset: 1 Ph 1DDN-A-0101Phase 1 · Alzheimer's DiseaseWeak signalNone on record————
Pharmacosmos logo
PharmacosmosPrivate
1 asset: 1 approvedApproved assets only30 Apr 2027Ferric derisomaltose · Phase 3————
Pharmanovia logo
PharmanoviaPrivate
3 assets: 2 approved, 1 Ph 3Diazepam (Libervant)Phase 3 · EpilepsyWeak signalDec 2026Solriamfetol · Phase 3————
PharmatrophiX logo
PharmatrophiXPrivate
1 asset: 1 Ph 2LM11A-31Phase 1/2 · Alzheimer's DiseaseWeak signalNone on record————
P
Phebra Pty LtdPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Pheon Therapeutics logo
Pheon TherapeuticsPrivate
1 asset: 1 Ph 1PHN-012Phase 1 · Non-Small Cell Lung CancerSep 2027PHN-012 · Phase 1————
P
Phoenix Labs Unlimited CompanyPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Phrontline Biopharma logo
Phrontline BiopharmaPrivate
1 asset: 1 Ph 1TJ101Phase 1 · Non-Small Cell Lung Cancer30 Dec 2026TJ101 · Phase 1————
Pierre Fabre Medicament logo
Pierre Fabre MedicamentPrivate
7 assets: 3 approved, 3 Ph 2, 1 Ph 1ElticertinibPhase 1/2 · Non-Small Cell Lung Cancer31 Mar 2027Binimetinib · Phase 3————
Pinnacle Biologics, Inc. logo
Pinnacle Biologics, Inc.Private
1 asset: 1 approvedApproved assets onlyNone on record————
Plexium, Inc. logo
Plexium, Inc.Private
1 asset: 1 Ph 1PLX-61639Phase 1 · Non-Small Cell Lung CancerDec 2029PLX-61639 · Phase 1————
P
Polpharma S.A.Private
1 asset: 1 otherAflibercept (Vgenfli)Age-Related Macular DegenerationNone on record————
Population Council logo
Population CouncilPrivate
1 asset: 1 Ph 3DapivirinePhase 3 · HIVReliable signalNone on record————
P
Poseida Therapeutics, Inc.Private
1 asset: 1 Ph 1P-BCMA-ALLO1Phase 1 · Multiple MyelomaMar 2029P-BCMA-ALLO1 · Phase 1————
Priavoid GmbH logo
Priavoid GmbHPrivate
1 asset: 1 Ph 2PRI-002Phase 2 · Alzheimer's DiseasePartial signalNone on record————
Prime Gene Therapeutics logo
Prime Gene TherapeuticsPrivate
1 asset: 1 Ph 3pumecitinibPhase 3 · Atopic DermatitisNone on record————
Primelink BioTherapeitics(ShenZhen) Limited logo
Primelink BioTherapeitics(ShenZhen) LimitedPrivate
1 asset: 1 Ph 1PLB-002Phase 1 · Non-Small Cell Lung Cancer30 Jun 2027PLB-002 · Phase 1————
P
Primus PharmaceuticalsPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Priothera SAS logo
Priothera SASPrivate
1 asset: 1 Ph 3mocravimodPhase 3 · Acute Myeloid LeukemiaMay 2027mocravimod · Phase 3————
P
Promedico Ltd.Private
1 asset: 1 approvedApproved assets onlyDec 2026Selinexor · Phase 2/3————
Promontory Therapeutics Inc. logo
Promontory Therapeutics Inc.Private
1 asset: 1 Ph 2ImifoplatinPhase 2 · Non-Small Cell Lung CancerWeak signalNone on record————
Pulmovant logo
PulmovantPrivate
1 asset: 1 Ph 3MosliciguatPhase 3 · Pulmonary Hypertension Associated with Interstitial Lung DiseaseDec 2026Mosliciguat · Phase 2————
PureIMS logo
PureIMSPrivate
1 asset: 1 Ph 1Levodopa CyclopsPhase 1 · Parkinson's DiseasePartial signalNone on record————
PurGenesis Technologies logo
PurGenesis TechnologiesPrivate
1 asset: 1 Ph 2PUR 0110Phase 2 · Atopic DermatitisNone on record————
P
Pyros PharmaceuticalsPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
Qidong Gaitianli Medicines Co., Ltd. logo
Qidong Gaitianli Medicines Co., Ltd.Private
1 asset: 1 Ph 3Huaier GranulePhase 3 · Non-Small Cell Lung CancerNone on record————
Qilu Pharmaceutical logo
Qilu PharmaceuticalPrivate
22 assets: 14 Ph 3, 5 Ph 2, 3 Ph 1AfuresertibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signalNov 2026QLS1304 · Phase 1————
Qingdao Sino-Cell Biomedicine Co., Ltd. logo
Qingdao Sino-Cell Biomedicine Co., Ltd.Private
1 asset: 1 Ph 2HS-IT101Phase 2 · MelanomaNone on record————
Q
QuantumCell ApSPrivate
1 asset: 1 Ph 1ACD856Phase 1 · Alzheimer's DiseasePartial signalNone on record————
Quetzal Therapeutics logo
Quetzal TherapeuticsPrivate
1 asset: 1 Ph 3Arsenic trioxide (QTX-2101)Phase 3 · Acute Myeloid LeukemiaMar 2027Arsenic trioxide (QTX-2101) · Phase 3————
R
R-PharmPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
R
Radius PharmaceuticalsPrivate
1 asset: 1 approvedApproved assets onlyNov 2026Elacestrant · Phase 2————
Rapa Therapeutics LLC logo
Rapa Therapeutics LLCPrivate
1 asset: 1 Ph 2RAPA-201Phase 2 · Multiple MyelomaWeak signal1 Mar 2029RAPA-201 · Phase 2————
R
Rare Disease TherapeuticsPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
ReAlta Life Sciences logo
ReAlta Life SciencesPrivate
1 asset: 1 Ph 2PegtarazimodPhase 2 · Chronic Obstructive Pulmonary DiseaseDec 2026Pegtarazimod · Phase 2————
RedCloud Bio logo
RedCloud BioPrivate
1 asset: 1 Ph 2H002Phase 1/2 · Non-Small Cell Lung CancerWeak signalNone on record————
R
RednviaPrivate
1 asset: 1 Ph 3EvogliptinPhase 3 · Type 2 DiabetesReliable signalNone on record————
Regend Therapeutics logo
Regend TherapeuticsPrivate
3 assets: 1 Ph 3, 2 Ph 1REGEND001Phase 3 · Chronic Obstructive Pulmonary DiseasePartial signal15 Feb 2027REGEND007 · Phase 1————
Regeneration Biomedical, Inc. logo
Regeneration Biomedical, Inc.Private
1 asset: 1 Ph 2RB-ADSCPhase 2 · Alzheimer's DiseaseSep 2028RB-ADSC · Phase 1————
Regor Pharmaceuticals logo
Regor PharmaceuticalsPrivate
1 asset: 1 Ph 2regor GLP-1Phase 2 · ObesityPartial signalNone on record————
Reistone Biopharma logo
Reistone BiopharmaPrivate
3 assets: 2 Ph 3, 1 Ph 2RSS0393Phase 3 · PsoriasisPartial signal13 Dec 2026ivarmacitinib · Phase 3————
Remedy Plan, Inc. logo
Remedy Plan, Inc.Private
1 asset: 1 Ph 1RPT1GPhase 1 · Acute Myeloid Leukemia1 Dec 2028RPT1G · Phase 1————
Remix Therapeutics logo
Remix TherapeuticsPrivate
1 asset: 1 Ph 1REM-422Phase 1 · Acute Myeloid Leukemia31 Jul 2027REM-422 · Phase 1————
Replicor Inc. logo
Replicor Inc.Private
1 asset: 1 Ph 2REP 2139-MgPhase 2 · Chronic Hepatitis BNone on record————
Retension Pharmaceuticals logo
Retension PharmaceuticalsPrivate
1 asset: 1 Ph 2RTN-001Phase 2 · HypertensionMar 2027RTN-001 · Phase 2————
Rezera logo
RezeraPrivate
1 asset: 1 Ph 2RuvonoflastPhase 2 · ObesityPartial signalNone on record————
R
Rgene CorporationPrivate
1 asset: 1 Ph 2BLEX 404Phase 1/2 · Non-Small Cell Lung Cancer30 Apr 2027BLEX 404 · Phase 2————
Rise Therapeutics logo
Rise TherapeuticsPrivate
1 asset: 1 Ph 1R-3750Phase 1 · Ulcerative Colitis30 Apr 2028R-3750 · Phase 1————
Risen (Suzhou) Pharma Tech Co., Ltd. logo
Risen (Suzhou) Pharma Tech Co., Ltd.Private
2 assets: 1 Ph 3, 1 Ph 2JS105Phase 3 · HR+/HER2- Metastatic Breast Cancer26 Feb 2027JS105 · Phase 1/2————
R
River 2 RenalPrivate
1 asset: 1 Ph 2R2R01Phase 2 · Heart FailureWeak signal1 Apr 2027R2R01 · Phase 2————
Rivus Pharmaceuticals logo
Rivus PharmaceuticalsPrivate
1 asset: 1 Ph 2HU6Phase 2 · Heart FailurePartial signalFeb 2027HU6 · Phase 2————
Rona Therapeutics logo
Rona TherapeuticsPrivate
3 assets: 1 Ph 2, 2 Ph 1RN0361Phase 1/2 · HypertriglyceridemiaNone on record————
Rondo Therapeutics logo
Rondo TherapeuticsPrivate
1 asset: 1 Ph 1RNDO-564Phase 1 · Non-Small Cell Lung Cancer28 Feb 2029RNDO-564 · Phase 1————
R
Rosemont PharmaceuticalsPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
S
S-Evans BiosciencesPrivate
1 asset: 1 Ph 2Menstrual blood-derived mesenchymal stem cells (MenSCs)Phase 1/2None on record————
Sairopa B.V. logo
Sairopa B.V.Private
1 asset: 1 Ph 1ADU-1805Phase 1 · Non-Small Cell Lung CancerMay 2027ADU-1805 · Phase 1————
Salubris Biotherapeutics Inc logo
Salubris Biotherapeutics IncPrivate
1 asset: 1 Ph 2JK08Phase 1/2 · Non-Small Cell Lung CancerWeak signalNone on record————
Samsung Bioepis logo
Samsung BioepisPrivate
5 assets: 5 approvedApproved assets onlyNone on record————
Sanwa Kagaku Kenkyusho logo
Sanwa Kagaku KenkyushoPrivate
3 assets: 2 Ph 3, 1 otherMiglitolUS approval withdrawn · Type 2 DiabetesPartial signal31 Mar 2027Anagliptin · Approved————
Sardocor (Medera Biopharma) logo
Sardocor (Medera Biopharma)Private
1 asset: 1 Ph 2AAV1.SERCA2aPhase 1/2 · Heart FailureOct 2027AAV1.SERCA2a · Phase 1————
Sarfez Pharmaceuticals logo
Sarfez PharmaceuticalsPrivate
1 asset: 1 approvedApproved assets onlyNone on record————
S
Sato Pharmaceutical Co., Ltd.Private
3 assets: 3 approvedApproved assets only27 Apr 2028Roflumilast (Zoryve) · Phase 3————
S
SatRxPrivate
1 asset: 1 Ph 3GosogliptinPhase 3 · Type 2 DiabetesPartial signalNone on record————
S
Scilex BioPrivate
1 asset: 1 Ph 2TisolagilinePhase 2 · Obesity31 Jan 2027Tisolagiline · Phase 2————
ScinnoHub Pharmaceutical Co., Ltd. logo
ScinnoHub Pharmaceutical Co., Ltd.Private
1 asset: 1 Ph 1SNH-118110Phase 1 · Non-Small Cell Lung Cancer26 Jun 2027SNH-118110 · Phase 1————
Sciwind Biosciences logo
Sciwind BiosciencesPrivate
3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1ecnoglutidePhase 3 · ObesityReliable signal5 Jan 2027Ecnoglutide (VRB-101) · Phase 1/2————
scPharmaceuticals logo
scPharmaceuticalsPrivate
1 asset: 1 approvedApproved assets onlyNone on record—$41MJun 2025Ended Jan 2026$15M
SDK Therapeutics logo
SDK TherapeuticsPrivate
1 asset: 1 Ph 3Arsenic trioxide (SDK001)Phase 3 · Acute Myeloid LeukemiaPartial signalJun 2027Arsenic trioxide (SDK001) · Phase 3————
Seagen logo
SeagenPrivate
5 assets: 2 approved, 2 Ph 3, 1 Ph 1Fetrastobart vedotinPhase 3 · Non-Small Cell Lung Cancer5 Jan 2028Fetrastobart vedotin · Phase 1————
Seanergy Dermatology logo
Seanergy DermatologyPrivate
1 asset: 1 Ph 1SNG100Phase 1 · Atopic DermatitisWeak signalNone on record————
Second Life Therapeutics logo
Second Life TherapeuticsPrivate
1 asset: 1 Ph 2SL-28Phase 1/2 · Non-Small Cell Lung Cancer1 Jan 2027SL-28 · Phase 1/2————
Secretome Therapeutics logo
Secretome TherapeuticsPrivate
1 asset: 1 Ph 1STM01Phase 1 · Heart FailureNone on record————
S
Seismic PharmaPrivate
1 asset: 1 Ph 3IstaroximePhase 2/3 · Heart FailurePartial signalDec 2028Istaroxime · Phase 2/3————
Seismic Therapeutic logo
Seismic TherapeuticPrivate
1 asset: 1 Ph 1S-4321Phase 1 · Psoriatic ArthritisSep 2027S-4321 · Phase 1————
selectION Therapeutics logo
selectION TherapeuticsPrivate
1 asset: 1 Ph 1si-544Phase 1 · PsoriasisPartial signalNone on record————
Servier logo
ServierPrivate
6 assets: 2 approved, 2 Ph 3, 2 Ph 2TeneligliptinPhase 3 · Type 2 DiabetesReliable signal31 Dec 2026Ivosidenib · Phase 1————
SFA Therapeutics logo
SFA TherapeuticsPrivate
1 asset: 1 Ph 3SFA-002Phase 2/3 · PsoriasisNone on record————
S
Shandong New Time Pharmaceutical Co., Ltd.Private
1 asset: 1 Ph 3F182112Phase 3 · Multiple Myeloma31 Dec 2027F182112 · Phase 1————
Shanghai Allink Biotherapeutics Co., Ltd. logo
Shanghai Allink Biotherapeutics Co., Ltd.Private
1 asset: 1 Ph 2ALK202Phase 2 · Non-Small Cell Lung CancerDec 2027ALK202 · Phase 1————
Shanghai Argo Biopharmaceutical logo
Shanghai Argo BiopharmaceuticalPrivate
2 assets: 2 Ph 2BW-00112Phase 2 · Hypertriglyceridemia26 Apr 2027BW-20829 · Phase 2————
Shanghai Auzone Biological Technology logo
Shanghai Auzone Biological TechnologyPrivate
1 asset: 1 Ph 3Edaravone (TTYP01)Phase 3 · Acute Ischemic Stroke23 Oct 2028Edaravone (TTYP01) · Phase 2————
Shanghai Cell Therapy Group Co., Ltd. logo
Shanghai Cell Therapy Group Co., Ltd.Private
2 assets: 2 Ph 1BZE2204Phase 1 · Systemic Lupus Erythematosus31 Dec 2026CD19/CD20/BCMA CAR-T (Shanghai Cell Therapy Group) · Phase 1————
Shanghai CureGene Pharmaceutical logo
Shanghai CureGene PharmaceuticalPrivate
1 asset: 1 Ph 1Evategrel (CG-0255)Phase 1 · Atherosclerotic Cardiovascular DiseaseNone on record————
Shanghai EpimAb Biotherapeutics logo
Shanghai EpimAb BiotherapeuticsPrivate
1 asset: 1 Ph 2BafisontamabPhase 2 · Advanced Metastatic Colorectal CancerWeak signal30 Dec 2027Bafisontamab · Phase 2————
Shanghai Green Valley Pharmaceuticals logo
Shanghai Green Valley PharmaceuticalsPrivate
1 asset: 1 Ph 3Sodium oligomannatePhase 3 · Alzheimer's DiseaseReliable signalNone on record————
Shanghai HEP Pharmaceutical logo
Shanghai HEP PharmaceuticalPrivate
1 asset: 1 Ph 3hepalatidePhase 3 · Chronic Hepatitis DeltaJun 2028hepalatide · Phase 3————

Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.

Page123456789101112131415